[Progress in targeted drug therapy for pulmonary hypertension associated with hypoxia]

Hypoxia-associated pulmonary hypertension (PH) is a severe complication secondary to chronic lung diseases and/or hypoxia, significantly increasing patient mortality risk. Its core pathophysiological mechanisms involve multiple pathways, including hypoxic pulmonary vasoconstriction, active pulmonary vascular remodeling, endothelial dysfunction, and inflammatory responses. Targeted drug therapy in this field has long faced significant challenges. Clinical trials of classic targeted drugs for pulmonary arterial hypertension (PAH) in hypoxia-associated PH have yielded inconsistent results; some drugs may even exacerbate the disease by potentially worsening ventilation/perfusion mismatch. While research on classic targeted therapies continues, studies investigating drugs targeting alternative pathways, such as directly reversing pulmonary vascular remodeling, are gaining momentum. This article will focus on the progress of both classic and emerging targeted drug research for hypoxia-associated PH.